Drug
Dabigatran etexilate mesylate
Dabigatran etexilate mesylate is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph early_phase_1
1
25%
Ph phase_4
1
25%
Ph phase_1
2
50%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 41 (25.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
NCT02945020
terminatedphase_1
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
NCT03807856
completedearly_phase_1
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
NCT04459585
completedphase_4
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
NCT01976507
Clinical Trials (4)
Showing 4 of 4 trials
NCT02945020Phase 1
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
NCT03807856Phase 1
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
NCT04459585Early Phase 1
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
NCT01976507Phase 4
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4